The discovery of immune checkpoint inhibitors such as programmed cell death ligand-1 (PD-L1) or programmed cell death-1 (PD-1) monoclonal antibodies have improved the overall survival of various types of cancers over the past decade. Here, PDCD1 is linked to cancer.